Exhibition and Sponsorship Prospectus

Co-chairs: Hagop Kantarjian, MD Professor and ChairDepartment of LeukemiaMD Anderson Cancer Center Houston, TX, USA

Srdan Verstovsek, MD, PhDProfessor of Medicine Department of Leukemia MD Anderson Cancer Center Houston, TX, USA

Boris Labar, MD, PhD Associate Professor Department of Medicine Clinical Hospital Center Zagreb Zagreb, Croatia

Organized by:

3-5 October 2018

Valamar Lacroma Dubrovnik Hotel Dubrovnik, Croatia

Linking Knowledge and Practice

LEUKEMIA AND LYMPHOMAEurope and the US

DUBROVNIK

A collaboration by:The University of Texas MD Anderson Cancer CenterThe School of Medicine University of ZagrebCroatian Leukemia and Lymphoma Society

DOOW NAHTANOJSETAICOSSA &

An MDedge Company

Leukemia and Lymphoma 2018 organizer: Jonathan Wood & Associates, an MDedge Company 7 Century DriveParsippany, NJ 07054Phone: 201-594-0400Email: info@jwoodassoc.comwww.leuk-lymph.com

Leuk-Lymph.com

LEUKEMIA AND LYMPHOMAEurope and the US Linking Knowledge and PracticeValamar Lacroma Dubrovnik Hotel, Dubrovnik, Croatia 3-5 October, 2018

Dear Colleagues and Friends,It is our great pleasure to announce the multinational congress Leukemia & Lymphoma 2018 that will take place at the Valamar Lacroma Dubrovnik Hotel, Dubrovnik, Croatia, scheduled for 3-5 October 2018. We would like to invite you to be a part of this premier event!

This meeting is a joint effort of The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; The School of Medicine, University of Zagreb, Zagreb, Croatia, organized by Jonathan Wood & Associates, an MDedge Company. The theme of the meeting, Europe and the US Linking Knowledge and Practice, reflects the collaboration to advance the research and treatment of patients with hematologic malignancies globally.

Leukemia & Lymphoma 2018 will host nearly 500 delegates and approximately 50 renowned faculty from the US and Europe. The meeting will provide participants with a unique opportunity for sharing knowledge, skills, and experiences. In addition, this activity will provide a platform for networking with many of the world’s leading experts, focusing on reviewing and assessing best practices and state of the art treatments across the spectrum of hematologic malignancies, including leukemias, lymphoma, myeloma, MDS, MPNs, and transplant.

The meeting program will include presentations, round-table discussions, debates with audience participation, oral abstracts, poster sessions, and a number of informal social gatherings. As the Chairs of Leukemia & Lymphoma 2018, it is our pleasure to invite you to participate in this one-of-a-kind event.

If you would like additional information or have any questions regarding the conference, please email BD@jwoodassoc.com, or contact Damaris Cruz at +1-201-594-0400 or by email, dcruz@jwoodassoc.com

Hagop Kantarjian, MD Professor Of Medicine Department of Leukemia MD Anderson Cancer CenterHouston, TX, USA

Srdan Verstovsek, MD, PhDProfessor of Medicine Department of Leukemia MD Anderson Cancer CenterHouston, TX, USA

Boris Labar, MD, PhD Associate Professor Department of Medicine Clinical Hospital Center ZagrebZagreb, Croatia

CORPORATE SPONSORSHIP OPPORTUNITIES

L eukemia & Lymphoma 2018 offers a forum for industry sponsors to participate in the exchange of information and ideas surrounding cutting edge developments in hematologic malignancies. The planning committee, faculty, and attendees alike appreciate the support

of our industry partners. Without your contributions, educational events such as Leukemia & Lymphoma 2018 would not be possible.

There are many opportunities for industry to sponsor the conference’s educational programs, meeting materials, and services. Each opportunity promises to provide a significant presence for companies during the conference. Commensurate with the level of contribution, sponsors are acknowledged in all Leukemia & Lymphoma 2018 meeting materials and on the conference website.

Corporate

Spon

sors

hip Opp

ortunities

Program A

t A G

lance

Registration

Keynote Address

Acute Lymphocytic Leukemias

Acute Myeloid Leukemias

Welcome Dinner

Morning Symposium

Myeloproliferative Neoplasms

Myelodysplactic Syndromes

Lunch Symposium

Chronic Myeloid Leukemias

Chronic Lymphocytic Leukemias

Oral Poster Presentations

Poster Walk Reception

Morning Symposium

B-Cell Lymphomas

T-Cell Lymphomas

Lunch Symposium

Multiple Myeloma

Wednesday, October 03 Thursday, October 04 Friday, October 05

7:157:308:008:158:308:459:009:159:309:45

10:0010:1510:3010:4511:0011:1511:3011:4512:0012:1512:3012:4513:0013:1513:3013:4514:0014:1514:3014:4515:0015:1515:3015:4516:0016:1516:3016:4517:0017:1517:3017:4518:0018:1518:3018:4519:0019:1519:3019:4520:0020:1520:3020:4521:00

DAY 1 Wednesday, October 3, 2018 14:00-14:10 Welcome and Introduction of Keynote

Presenter Boris Labar (Croatia)

14:10-15:00 Keynote Address: State of the Art Therapy for CML Hagop Kantarjian (USA)

SESSION 1: ACUTE LYMPHOCYTIC LEUKEMIASModerators: Boris Labar, Farhad Ravandi15:05-15:20 Prognostic implications of cytogenetic

aberrations and molecular mutations in acute leukemia Claudia Haferlack (Germany)

15:25-15:40 Significance of minimal residual disease in the acute leukemias Monika Bruggemann (Germany)

15:45-16:00 Impact of TKIs on Philadelphia chromosome+ ALL Elias Jabbour (USA)

16:05-16:20 Therapeutic options for Philadelphia chromosome-like ALL Sabina Chiaretti (Italy)

16:25-16:40 Treatment of Adolescents and Young Adults with ALL Jean-Pierre Marie (France)

16:45-17:00 How should we treat older patients with ALL? Max Topp (Germany)

17:05-17:20 BREAK

SESSION 2: ACUTE MYELOID LEUKEMIASModerators: Boris Labar, Farhad Ravandi17:20-17:35 Targeted therapy for AML using FLT3 and

IDH1/2 inhibitors Stephane de Botton (France)

17:40-17:55 Monoclonal antibodies and checkpoint inhibitors in AML Farhad Ravandi (USA)

18:00-18:15 CPX351 and other novel therapies for AML Jeffrey Lancet (USA)

18:20-18:35 CAR T cell therapy for acute leukemia Stephen Grupp (USA)

18:40-19:00 How will solving GVHD impact transplantation for acute leukemias? Nikolas von Bubnoff (Germany)

19:00 Welcome Dinner/Reception

DAY 2 Thursday, October 4, 2018 7:30-9:00 Morning Symposium

SESSION 3: MYELOPROLIFERATIVE NEOPLASMSModerators: Pierre Fenaux, Srdan Verstovsek9:05-9:20 Polycythemia Vera: Diagnosis and

managementAlessandro Vannucchi (Italy)

9:25-9:40 Primer on atypical myeloproliferative neoplasms Andreas Reiter (Germany)

9:45-10:00 What exactly is myelomonocytic leukemia? Differentiating CMML from everything else Nadira Durakovic (Croatia)

10:05-10:20 JAK inhibitors for all classical Philadelphia negative MPN Srdan Verstovsek (USA)

10:25-10:40 The MPN QOL International Study Group: Is quality of life a legitimate therapeutic target? Claire Harrison (UK)

10:45-11:00 Stem cell transplantation for Philadelphia chromosome-negative MPNs in 2018 Jane Apperley (UK)

11:05-11:20 BREAK

SESSION 4: MYELODYSPLASTIC SYNDROMESModerators: Pierre Fenaux, Srdan Verstovsek11:20-11:35 ICUS/CHIP/CCUS: What determines a

correct diagnosis? Ghulam Mufti (UK)

11:40-11:55 Molecular determinants of MDS Luca Malcovati (Italy)

12:00-12:15 Frontline therapy of low-risk MDS Valeria Santini (Italy)

12:20-12:35 Frontline therapy of high-risk MDS Uwe Platzbecker (Germany)

12:40-12:55 What novel new therapies may mean for the future of MDS Pierre Fenaux (France)

13:00-13:20 When should transplant be offered as an option for MDS Mateo Della Porta (Italy)

13:20-15:00 Lunch Symposium

AGENDA Pr

ogra

m A

gend

a

SESSION 5: CHRONIC MYELOID LEUKEMIASModerators: Michael Hallek, Hagop Kantarjian15:00-15:15 Is minimal residual disease as significant

in chronic leukemias as it is in acute leukemias? William Wierda (USA)

15:20-15:35 Modulating the efficacy of tyrosine kinase inhibitors in CML Jorge Cortes (USA)

15:40-15:55 What have we learned from the CML European Treatment and Outcomes Study? Michele Baccarani (Italy)

16:00-16:15 How quality of life issues impact choice of therapy for CML: GIMEMA and EORTC Quality of Life Group Fabio Efficace (Italy)

16:20-16:35 BREAK

SESSION 6: CHRONIC LYMPHOCYTIC LEUKEMIASModerators: Michael Hallek, Hagop Kantarjian16:35-16:50 Molecular signature of CLL

Davide Rossi (Italy)16:55-17:10 Frontline therapy in CLL

Michael Hallek (Germany)17:15-17:30 Therapy of older patients with CLL

Emili Montserrat (Spain)17:35-17:50 Novel agents in CLL

Susan O’Brien (USA)17:55-18:15 Transplantation for CLL

Peter Dreger (Germany)

SESSION 7: ORAL POSTER PRESENTATIONS18:15-19:00 TBA 19:00-20:00 Poster walk reception

DAY 3 Friday,October 5, 2018 7:30-9:00 Morning Symposium

SESSION 7: B-CELL LYMPHOMASModerators: Tim Illidge, Nathan Fowler9:05-9:20 Overcoming anti-CD20 refractory disease

in BCL with newer antibodies Guillaume Cartron (France)

9:25-9:40 Managing relapsed/refractory Hodgkin lymphoma Tim Illidge (UK)

9:45-10:00 Targeting the microenvironment in B-cell lymphoma Nathan Fowler (USA)

10:05-10:20 Next generation approaches in primary CNS lymphoma Gerald Illerhaus (Germany)

10:25-10:40 Looking beyond R-CHOP in diffuse large B-cell lymphomaMarek Trneny (Czech Republic)

10:45-11:00 Moving beyond CHOP in mantle cell lymphoma Simon Rule (UK)

11:25-11:40 BREAK

SESSION 8: T-CELL LYMPHOMASModerators: Madeleine Duvic, Ali Bazarbachi11:45-12:00 Integrating immunotherapy into

treatment paradigms for CTCL Madeleine Duvic (USA)

12:05-12:20 Targeting the T-cell receptor pathway in peripheral T-cell lymphoma Pier Luigi Zinzani (Italy)

12:25-12:40 Enhancing targeted therapies with epigenetic agents in PTCL Owen O’Connor (USA)

12:45-13:05 Is there a role for ASCT in adult T-cell lymphoma? Ali Bazarbachi (Lebanon)

13:05-14:35 Lunch Symposium

SESSION 9: MULTIPLE MYELOMAModerators: Nikhil Munshi, Pieter Sonneveld14:35-14:50 Prognostic factors in multiple myeloma

Jesus San Miguel (Spain)14:55-15:10 Managing asymptomatic multiple

myeloma Dirk Hose (Germany)

15:15-15:30 Immunotherapy for multiple myeloma: update on the IMIDS Nikhil Munshi (USA)

15:35-15:50 Maintenance therapy in multiple myeloma Pieter Sonneveld (The Netherlands)

15:55-16:10 Minimal residual disease in multiple myeloma Herve Avet-Loiseau (France)

16:15-16:35 New antibodies for multiple myeloma Antonio Palumbo (Italy)

16:35 Closing remarks

Program A

genda

LEUK-LYMPH.COM